51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)ICAAC: New Integrase Inhibitor BI 224436 Active against Raltegravir-Resistant HIV
- Details
- Category: HIV Treatment
- Published on Friday, 07 October 2011 00:00
- Written by Liz Highleyman
Boehringer Ingelheim's novel integrase inhibitor candidate BI 2244336, which works by a different mechanism than existing drugs in its class, demonstrated potent antiviral activity and a good pharmacokinetic profile in a series of early studies presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.
ICAAC: Declining Prevalence of HIV Triple-class and Protease Inhibitor Resistance
- Details
- Category: HIV Treatment
- Published on Friday, 07 October 2011 00:00
- Written by Liz Highleyman
HIV strains showing resistance to protease inhibitors, or to all 3 of the earliest classes of antiretroviral drugs, have become less common over the past several years, making it easier to construct effective regimens, researchers reported at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.
ICAAC: Monoclonal Antibody Ibalizumab May Hold Promise for Treatment-Experienced HIV Patients
- Details
- Category: HIV Treatment
- Published on Tuesday, 04 October 2011 00:00
- Written by Liz Highleyman
Ibalizumab (also known as TMB-355, formerly TNX-355) -- an antibody-based therapy for HIV -- was well-tolerated and significantly reduced viral load over 24 weeks when used with optimized background therapy, researchers reported at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.
ICAAC: Double Dose of Hepislav Works as Well as 3 Doses of Standard HBV Vaccine
- Details
- Category: HBV Prevention
- Published on Friday, 07 October 2011 00:00
- Written by Press Release
Two injections of Dynavax's investigational Hepislav hepatitis B virus (HBV) vaccine protected adults over age 40 as well as the standard regimen consisting of 3 doses of the Engerix-B vaccine given over 6 months, researchers reported at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.
ICAAC: HPV Testing and Pap Smears Identify Anal Cancer Risk in HIV+ Men
- Details
- Category: Human Papillomavirus (HPV)
- Published on Friday, 30 September 2011 00:00
- Written by Liz Highleyman
Human papillomavirus (HPV) testing and anal Pap testing can detect abnormal cell changes that could progress to anal cancer in HIV positive gay men at an earlier and more treatable stage, and is likely to be cost-effective, according to a study presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this month in Chicago.
More Articles...
- ICAAC: Omitting Inactive NRTIs from Salvage Regimen Can Maintain Viral Suppression
- ICAAC: Maraviroc May Reduce Liver Fibrosis in HIV/HCV Coinfected People
- ICAAC: Lopinavir/ritonavir Reduces Mother-to-Child HIV Transmission during Supplemental Breastfeeding
- ICAAC: Cobicistat Matches Ritonavir as Booster, Studies Clarify Effects on Kidney Function
- ICAAC: Zinc Finger Gene Therapy Boosts CD4 Cells, May Lower HIV Viral Load
- ICAAC: Raltegravir is Effective and Well-tolerated in Diverse Populations with HIV
- ICAAC: Didanosine, Higher HCV Viral Load Predict Liver Fibrosis in HIV/HCV Coinfected People
- ICAAC: BMS-790052 plus Standard Therapy Cures Most Genotype 1 Hepatitis C Patients
- ICAAC: HCV Drug Telaprevir Shows No Problematic Interactions with Raltegravir
Web Design and Development by